Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Povorcitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China
    CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China

    04 Apr 2024

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/24039/cms-and-incyte-collaborate-to-develop-vitiligo-drug-povorcitinib-in-china-and-southeast-asia.html

    BIOSPECTRUM ASIA
    04 Apr 2024
    Share Share
    Incyte and CMS Announce Collab and License Agreement for Povorcitinib in Asia
    Incyte and CMS Announce Collab and License Agreement for Povorcitinib in Asia

    01 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240401280916/en

    BUSINESSWIRE
    01 Apr 2024
    Share Share
    Incyte's oral Dupixent rival hits in midphase skin disease trial
    Incyte's oral Dupixent rival hits in midphase skin disease trial

    12 Mar 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/incyte-itching-piece-dupixents-market-hits-goals-midphase-skin-disease-trial

    FIERCE BIOTECH
    12 Mar 2024
    Share Share
    Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib
    Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib

    10 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240310275231/en

    BUSINESSWIRE
    10 Mar 2024
    Share Share
    Data From Incyte’s Povorcitinib Clinical Program to Be Featured
    Data From Incyte’s Povorcitinib Clinical Program to Be Featured

    13 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231013811765/en

    BUSINESSWIRE
    13 Oct 2023
    Share Share
    Incyte Announces Positive 52-Week Data from Phase 2b Evaluating Povorcitinib
    Incyte Announces Positive 52-Week Data from Phase 2b Evaluating Povorcitinib

    11 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231010468675/en

    BUSINESSWIRE
    11 Oct 2023
    Share Share